Bullish & Foolish
Full DARE fundamentals All 466 on the Survival Watch

DAREDARE BIOSCIENCE, INC.

Is Dare Bioscience struggling financially?

Yes, by its own account. Dare Bioscience told the SEC on 14 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

30/100

Fragile

Sector
Biotech/Pharma
Market cap
$19.2M
Source filing
10-Q 14 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 12months

    If the burn speeds up

    Empty by Jun 2027

  • 17months

    If it eases off

    Empty by Nov 2027

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$12.6M

÷

Cash burned over the last 12 months

$10.3M

What Dare Bioscience told the SEC

…sufficient revenues to finance its operations or achieve profitability. Based on the Company’s current analysis of the conditions described above, there is substantial doubt about the Company's ability to continue as a going concern within the 12 month period from the issuance date of the accompanying condensed consolidated financial statements given that the timing and amount of potential revenue the Company may…

DARE BIOSCIENCE, INC., Form 10-Q, filed 14 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 66.8% share-count increase The company issued stock. Each share now owns 40.1% less of the business than a year ago, before any change in the price.

Other Biotech/Pharma companies that filed the doubt